Beta-catenin immunohistochemistry is frequently very weak positive or even negative in hepatocellular neoplasm NOS, which is a clue to diagnosis along with pleomorphic appearance and macrotrabecular arrangement.
Once chemotherapy begins and the tumor gets replaced by pools of blood and fibrous tissue, there's nothing for the chemotherapy to kill, and the size doesn't decrease much further beyond a certain point.
Conventional hepatoblastoma is genomically quiet with very low mutation burden and invariably has either a point mutation or small deletion in exon 3 of the CTNNB1 gene.
Clinical & Research Update: Pediatric Liver Tumors - A Case-Based Discussion with Drs. Katherine Somers & Alex Bondoc
▶Ep 16 · 30:05
quotethe FIT trial, the AHP 1531 and the FIT trial actually mandated liver biopsy for diagnosis of the lesion before we start treatment.↗
▶Ep 16 · 30:05
guidelineThe FIT trial (AHEP 1531) mandated liver biopsy for diagnosis before starting treatment.↗
▶Ep 16 · 33:19
clinicalOnce chemotherapy begins and the tumor gets replaced by pools of blood and fibrous tissue, there's nothing for the chemotherapy to kill, and the size doesn't decrease much further beyond a certain point.↗
▶Ep 16 · 33:19
quoteonce chemotherapy begins and the tumor gets replaced by these pools of blood as well as fibrous tissue. There's nothing for the chemotherapy to kill.↗
▶Ep 16 · 1:02:23
clinicalConventional hepatoblastoma is genomically quiet with very low mutation burden and invariably has either a point mutation or small deletion in exon 3 of the CTNNB1 gene.↗
▶Ep 16 · 1:02:41
clinicalHepatocellular neoplasm NOS shows more genomic instability with chromosomal gains and losses, characterized by CTNNB1 deletion, often with large deletions or complete exon 3 skipping (exon 2 joined to exon 4).↗
▶Ep 16 · 1:03:19
clinicalBeta-catenin immunohistochemistry is frequently very weak positive or even negative in hepatocellular neoplasm NOS, which is a clue to diagnosis along with pleomorphic appearance and macrotrabecular arrangement.↗
▶Ep 16 · 1:03:51
clinicalHepatocellular neoplasm NOS can be targeted with high-risk hepatoblastoma therapy to shrink tumors and make them amenable to surgery in most cases.↗
Ranga's statements about Hepatocellular Carcinoma8 statements
Clinical & Research Update: Pediatric Liver Tumors - A Case-Based Discussion with Drs. Katherine Somers & Alex Bondoc
▶Ep 4 · 30:05
guidelineThe FIT trial (AHEP 1531) mandated liver biopsy for diagnosis before starting treatment.↗
▶Ep 4 · 30:05
quotethe FIT trial, the AHP 1531 and the FIT trial actually mandated liver biopsy for diagnosis of the lesion before we start treatment.↗
▶Ep 4 · 33:19
clinicalOnce chemotherapy begins and the tumor gets replaced by pools of blood and fibrous tissue, there's nothing for the chemotherapy to kill, and the size doesn't decrease much further beyond a certain point.↗
▶Ep 4 · 33:19
quoteonce chemotherapy begins and the tumor gets replaced by these pools of blood as well as fibrous tissue. There's nothing for the chemotherapy to kill.↗
▶Ep 4 · 1:02:23
clinicalConventional hepatoblastoma is genomically quiet with very low mutation burden and invariably has either a point mutation or small deletion in exon 3 of the CTNNB1 gene.↗
▶Ep 4 · 1:02:41
clinicalHepatocellular neoplasm NOS shows more genomic instability with chromosomal gains and losses, characterized by CTNNB1 deletion, often with large deletions or complete exon 3 skipping (exon 2 joined to exon 4).↗
▶Ep 4 · 1:03:19
clinicalBeta-catenin immunohistochemistry is frequently very weak positive or even negative in hepatocellular neoplasm NOS, which is a clue to diagnosis along with pleomorphic appearance and macrotrabecular arrangement.↗
▶Ep 4 · 1:03:51
clinicalHepatocellular neoplasm NOS can be targeted with high-risk hepatoblastoma therapy to shrink tumors and make them amenable to surgery in most cases.↗
Ranga's statements about Liver Tumors (Hepatoblastoma/HCC)16 statements
Clinical & Research Update: Pediatric Liver Tumors - A Case-Based Discussion with Drs. Katherine Somers & Alex Bondoc
▶Ep 17 · 30:05
guidelineThe FIT trial (AHEP 1531) mandated liver biopsy for diagnosis before starting treatment.↗
▶Ep 17 · 30:05
quotethe FIT trial, the AHP 1531 and the FIT trial actually mandated liver biopsy for diagnosis of the lesion before we start treatment.↗
▶Ep 17 · 30:05
guidelineThe FIT trial (AHEP 1531) mandated liver biopsy for diagnosis before starting treatment.↗
▶Ep 17 · 30:05
quotethe FIT trial, the AHP 1531 and the FIT trial actually mandated liver biopsy for diagnosis of the lesion before we start treatment.↗
▶Ep 17 · 33:19
clinicalOnce chemotherapy begins and the tumor gets replaced by pools of blood and fibrous tissue, there's nothing for the chemotherapy to kill, and the size doesn't decrease much further beyond a certain point.↗
▶Ep 17 · 33:19
clinicalOnce chemotherapy begins and the tumor gets replaced by pools of blood and fibrous tissue, there's nothing for the chemotherapy to kill, and the size doesn't decrease much further beyond a certain point.↗
▶Ep 17 · 33:19
quoteonce chemotherapy begins and the tumor gets replaced by these pools of blood as well as fibrous tissue. There's nothing for the chemotherapy to kill.↗
▶Ep 17 · 33:19
quoteonce chemotherapy begins and the tumor gets replaced by these pools of blood as well as fibrous tissue. There's nothing for the chemotherapy to kill.↗
▶Ep 17 · 1:02:23
clinicalConventional hepatoblastoma is genomically quiet with very low mutation burden and invariably has either a point mutation or small deletion in exon 3 of the CTNNB1 gene.↗
▶Ep 17 · 1:02:23
clinicalConventional hepatoblastoma is genomically quiet with very low mutation burden and invariably has either a point mutation or small deletion in exon 3 of the CTNNB1 gene.↗
▶Ep 17 · 1:02:41
clinicalHepatocellular neoplasm NOS shows more genomic instability with chromosomal gains and losses, characterized by CTNNB1 deletion, often with large deletions or complete exon 3 skipping (exon 2 joined to exon 4).↗
▶Ep 17 · 1:02:41
clinicalHepatocellular neoplasm NOS shows more genomic instability with chromosomal gains and losses, characterized by CTNNB1 deletion, often with large deletions or complete exon 3 skipping (exon 2 joined to exon 4).↗
▶Ep 17 · 1:03:19
clinicalBeta-catenin immunohistochemistry is frequently very weak positive or even negative in hepatocellular neoplasm NOS, which is a clue to diagnosis along with pleomorphic appearance and macrotrabecular arrangement.↗
▶Ep 17 · 1:03:19
clinicalBeta-catenin immunohistochemistry is frequently very weak positive or even negative in hepatocellular neoplasm NOS, which is a clue to diagnosis along with pleomorphic appearance and macrotrabecular arrangement.↗
▶Ep 17 · 1:03:51
clinicalHepatocellular neoplasm NOS can be targeted with high-risk hepatoblastoma therapy to shrink tumors and make them amenable to surgery in most cases.↗
▶Ep 17 · 1:03:51
clinicalHepatocellular neoplasm NOS can be targeted with high-risk hepatoblastoma therapy to shrink tumors and make them amenable to surgery in most cases.↗
Ranga's statements about Pediatric Oncology8 statements
Clinical & Research Update: Pediatric Liver Tumors - A Case-Based Discussion with Drs. Katherine Somers & Alex Bondoc
▶Ep 666 · 30:05
quotethe FIT trial, the AHP 1531 and the FIT trial actually mandated liver biopsy for diagnosis of the lesion before we start treatment.↗
▶Ep 666 · 30:05
guidelineThe FIT trial (AHEP 1531) mandated liver biopsy for diagnosis before starting treatment.↗
▶Ep 666 · 33:19
clinicalOnce chemotherapy begins and the tumor gets replaced by pools of blood and fibrous tissue, there's nothing for the chemotherapy to kill, and the size doesn't decrease much further beyond a certain point.↗
▶Ep 666 · 33:19
quoteonce chemotherapy begins and the tumor gets replaced by these pools of blood as well as fibrous tissue. There's nothing for the chemotherapy to kill.↗
▶Ep 666 · 1:02:23
clinicalConventional hepatoblastoma is genomically quiet with very low mutation burden and invariably has either a point mutation or small deletion in exon 3 of the CTNNB1 gene.↗
▶Ep 666 · 1:02:41
clinicalHepatocellular neoplasm NOS shows more genomic instability with chromosomal gains and losses, characterized by CTNNB1 deletion, often with large deletions or complete exon 3 skipping (exon 2 joined to exon 4).↗
▶Ep 666 · 1:03:19
clinicalBeta-catenin immunohistochemistry is frequently very weak positive or even negative in hepatocellular neoplasm NOS, which is a clue to diagnosis along with pleomorphic appearance and macrotrabecular arrangement.↗
▶Ep 666 · 1:03:51
clinicalHepatocellular neoplasm NOS can be targeted with high-risk hepatoblastoma therapy to shrink tumors and make them amenable to surgery in most cases.↗
